Forskning
Udskriv Udskriv
Switch language
Region Hovedstaden - en del af Københavns Universitetshospital
Udgivet

Predictors of Initial and Sustained Remission in Patients Treated with Antithyroid Drugs for Graves' Hyperthyroidism: The RISG Study

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

DOI

  1. Corrigendum to "Challenges in Interpretation of Thyroid Function Tests in Pregnant Women with Autoimmune Thyroid Disease"

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. Challenges in interpretation of thyroid function tests in pregnant women with autoimmune thyroid disease

    Publikation: Bidrag til tidsskriftReviewForskningpeer review

  3. Do Thyroid Disrupting Chemicals Influence Foetal Development during Pregnancy?

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskning

  1. Association between 3-Iodothyronamine (T1AM) Concentrations and Left Ventricular Function in Chronic Heart Failure

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. Levothyroxine/Liothyronine Combination Therapy and Quality of Life: Is It All about Weight Loss?

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  3. Kombinationsbehandling med thyroxin og trijodthyronin til patienter med hypotyreose

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  4. How should thyroid-related quality of life be assessed? Recalled patient-reported outcomes compared with here-and-now measures

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

Vis graf over relationer
Abstract Purpose. To study predictors of attaining (part 1) and sustaining (part 2) remission in patients with Graves’ hyperthyroidism (GH) treated with antithyroid drugs (ATD). Methods. In the prospective first part, the included patients were treated with ATD until a prespecified definition of remission (thyrotropin > 0.4 mU/L and TSH-receptor antibodies (TRAb) ≤ 1. 0 IU/L in a patient receiving a methimazole dose ≤ 5 mg/day, on two occasions two months apart) was met, or for 24 months. In the second part, patients attaining remission in part 1 were randomized to treatment or observation and followed until relapse or for 24 months. Results. 173 patients completed study 1 and 53% attained remission. TRAb and age were the only significant predictors of remission. Patients with baseline TRAb below vs above 10 IU/L attained remission in 63% compared to 39%, and 5 months priorly (p<0.001). In study 2, 96.4% of the patients randomized to treatment (n=33) sustained remission compared to 66% in the observation group (n=33). Treatment arm was the only significant parameter (p<0.001) of sustained remission. Conclusion. Baseline TRAb was prognostic for attaining remission in GH. Consecutive TRAb measurements during treatment were not worthwhile, but a single measurement after 6-8 months in patients with initial TRAb < 10 IU/L could substantially shorten the treatment period in a subgroup of patients. Only 3.6% of the patients in remission experienced relapse during follow-up when treated with a combination of fixed low dose methimazole and L-T4. ClinTrial.gov registration number is  NCT00796913.
OriginalsprogEngelsk
Artikelnummer5945178
TidsskriftJournal of thyroid research
Vol/bind2019
Antal sider9
ISSN2090-8067
DOI
StatusUdgivet - 2019

ID: 59310734